Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Director dealings: 3i execs buy the dip, AstraZeneca CFO offloads shares
(Sharecast News) - London-listed companies 3i Group and AstraZeneca disclosed fresh director dealings on Wednesday, with senior executives at the private equity group adding to their holdings while AstraZeneca's finance chief sold American Depositary Shares. 3i Group said chief executive Simon Borrows purchased 30,000 shares at 3,366.7p each on the London Stock Exchange on 13 November.
Peter Wirtz, another senior manager, bought 25,000 shares at 3,415.53p on the same day.
A further transaction was reported on 14 November, when Karen McKellar, the wife of director Peter McKellar, acquired 4,000 shares at 3,344.6736p.
All three purchases were notified to the company this week.
The transactions followed a sharp fall in 3i's share price on Wednesday, when the stock slid 11.4% to 3,606p after the FTSE 100 group flagged a tougher investment environment despite reporting a stronger second quarter.
Borrows said at the time that the private equity portfolio had "maintained good momentum" but warned that the transaction market and wider backdrop would remain challenging into the second half of the financial year.
The update highlighted continued strong growth at discount retailer Action, which drove a 13% total return and lifted net asset value to 2,857p per share.
AstraZeneca meanwhile reported that chief financial officer Aradhana Sarin sold 15,000 American Depositary Shares on 12 November at a price equivalent to $88.6345 per ordinary share.
The sale was executed on the Nasdaq, and disclosed to the company a day later.
Two ADSs represent one AstraZeneca share.
It came as AstraZeneca's shares traded near record highs, buoyed by stronger-than-expected quarterly earnings and a US drug-pricing agreement reached in October.
Reporting by Josh White for Sharecast.com.
Top Director Buys
Resolute Mining Limited Npv (di) (RSG) Director name: Parker ,Adrienne Amount purchased: 5,263 @ $4,894.59 Value: $21,242,043.66
London Btc Company Limited Npv (di) (BTC) Director name: Lenigas,David Amount purchased: 1,000,000 @ 350.00p Value: £3,500,000.00
3i Group (III) Director name: Borrows,Simon Amount purchased: 30,000 @ 3,366.70p Value: £1,010,009.99
Wpp (WPP) Director name: Rose ,Cindy Amount purchased: 50,000 @ 288.70p Value: £144,350.00
Wpp (WPP) Director name: Jansen ,Philip Amount purchased: 50,000 @ 285.10p Value: £142,550.00
Asiamet Resources Limited (di) (ARS) Director name: Djauhari,Eva Armila Amount purchased: 7,911,115 @ 1.50p Value: £118,666.72
Smiths News (SNWS) Director name: Malhotra,Manju Amount purchased: 30,006 @ 66.30p Value: £19,893.98
Experian (EXPN) Director name: DeRose,Kathleen Amount purchased: 250 @ $44.53 Value: $9,179.93
Xp Factory (XPF) Director name: Bird,Graham Amount purchased: 1,327 @ 11.30p Value: £149.95
Xp Factory (XPF) Director name: Harpham,Richard Amount purchased: 1,327 @ 11.30p Value: £149.95
Top Director Sells
Astrazeneca (AZN) Director name: Sarin,Aradhana Amount sold: 15,000 @ $88.63 Value: $1,096,328.42
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.